跳至主要内容
临床试验/EUCTR2009-012451-18-GB
EUCTR2009-012451-18-GB进行中(未招募)不适用

EUROACTION PLUS: Intensive smoking intervention (Varenicline) during a preventive cardiology programme for patients with established atherosclerotic disease, people at high cariovascular risk and their families - EUROACTION PLUS INTENSIVE SMOKING INTERVENTION (VARENICLINE)

Imperial College London0 个研究点目标入组 1,060 人开始时间: 2009年10月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
1,060

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1 Vascular patients and partners
  • All patients, men and women 18 years of age or older but less than 80 years, with a new or recurrent diagnosis of coronary or other atherosclerotic vascular disease, and who are continuing to smoke, will be eligible for the programme.
  • Patients may fulfill more than one of thefollowing criteria:
  • 1) Acute myocardial infarction (STEMI or NSTEMI)
  • 2) Unstable angina
  • 3) Stable angina pectoris
  • 4) Elective revascularisation:
  • - coronary artery by-pass graft (CABG)
  • - percutaneus transluminal angioplasty (PTCA)
  • 6)Transient iscaemic attack (TIA)
  • 7)Peripheral vascular disease (PVD)
  • The partners of all recruited vascular patients will also be identified and invited to participate in the programme.
  • 2. High-risk patients and partners
  • All high risk people who meet the following inclusion criteria: Men and women, 50 years of age or older, but less than 80 years, who are smokers and either
  • 1) are newly identified high multifactorial risk individuals: CVD risk equal or greater than 5% over 10 years (now or projected to age 60 years), according to the HeartScore risk estimation system; or
  • 2) have been treated with antihypertensive and/or lipid-lowering therapies in the last year; or
  • 3) have diabetes mellitus diagnosed within the last 3 years.
  • The partners of all recruited high risk patients will also be identified and invited to participate in the programme.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Vascular patients:
  • - severe heart failure
  • - severe physical disability
  • - impaired cognitive function
  • - patients with acute coronary syndromes, with or without revasularisation, will not be included in the study until 2 weeks has elapsed following their coronary event.
  • High risk people:
  • - history of coronary heart disease
  • - severe heart failure
  • - severe physical disability
  • - impaired cognitive function

研究者

相似试验

进行中(未招募)
不适用
EUROACTION PLUS: Intensive smoking intervention (Varenicline) during a preventive cardiology programme for patients with established atherosclerotic disease, people at high cariovascular risk and their families - EUROACTION PLUS INTENSIVE SMOKING INTERVENTION (VARENICLINE)
EUCTR2009-012451-18-NLImperial College London1,060
已完成
不适用
EUROACTION PLUS intensive smoking intervention (varenicline)
ISRCTN22073647Imperial College London (UK)1,060
已完成
4 期
Euroaction plus intensive smoking intervention (varenicline)prevention of cardiovascular diseasesmoking cessation1008220610003216
NL-OMON38232Clinical Research Governance Office,Sir Alexander Fleming Building, Imperial College212
进行中(未招募)
1 期
EUROACTION PLUS con intervención intensiva sobre el tabaco (vareniclina) durante un programa de cardiología preventiva para pacientes con enfermedad aterosclerosa establecida, individuos con alto riesgo cardiovascular y sus familias - EUROACTION PLUS CON INTERVENCIÓN INTENSIVA SOBRE EL TABACO (VARENICLINA)Pacientes fumadores con enfermedad cardiovascular u otra enfermedad aterosclerosa o individuos con riesgo elevado de padecer ECVMedDRA version: 12.1Level: LLTClassification code 10053325Term: Smoking cessation therapy
EUCTR2009-012451-18-ESImperial College London696
招募中
不适用
European action on secondary and primary prevention of coronary heart disease in order to reduce events (part III)atherosclerosis
NL-OMON30196Erasmus MC, Universitair Medisch Centrum Rotterdam800